Toronto Stock Exchange Symbol: DND
MISSISSAUGA, ON, April 25, 2012 /CNW/ - Cipher Pharmaceuticals Inc.
(TSX: DND; OTC: CPHMF.PK) today announced it will host a conference
call for its Q1 2012 financial results and hold its Annual Meeting of
Shareholders on Friday, May 4, 2012.
Q1 2012 CONFERENCE CALL
WHEN: Friday, May 4, 2012 at 8:30AM ET
CONFERENCE CALL/WEBCAST: You can join the call by dialing 647-427-7450
or 1-888-231-8191. A live audio webcast will be available through http://www.cipherpharma.com or http://www.newswire.ca. An archived replay of the webcast will be available for 365 days.
ANNUAL MEETING OF SHAREHOLDERS
WHEN: Friday, May 4, 2012 at 11:00AM ET
WHERE: Goodmans LLP, Bay Adelaide Centre, 333 Bay Street, Suite 3400,
WEBCAST: The meeting will be webcast live. To access the webcast go to http://www.cipherpharma.com or http://www.newswire.ca. Please connect at least 15 minutes prior to the start of the meeting
to ensure adequate time for any software download that may be required
to join the webcast. An archived replay of the webcast will be
available for 365 days.
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (TSX: DND; OTC: CPHMF.PK) is a growing specialty
pharmaceutical company that commercializes novel formulations of
successful, currently marketed molecules. Cipher's strategy is to
in-license clearly differentiated products, advance them through the
clinical development and regulatory approval stages, and out-license to
international marketing partners. The Company's first product is a
fenofibrate formulation marketed in the United States as Lipofen®.
Cipher's second product, an extended-release tramadol, is marketed in
the United States as ConZip™ and in Canada as Durela™. Cipher's New
Drug Application for its third product, a novel formulation of the acne
treatment isotretinoin, is currently being reviewed by the FDA and
Health Canada. For more information, please visit www.cipherpharma.com.